Q1 Earnings Estimate for Celcuity Issued By HC Wainwright

Celcuity, Inc. (NASDAQ:CELC) – Equities researchers at HC Wainwright issued their Q1 2027 EPS estimates for shares of Celcuity in a note issued to investors on Wednesday, June 3rd. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $145.00 target price on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($3.96) per share. HC Wainwright also issued estimates for Celcuity’s Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at $0.06 EPS and Q4 2027 earnings at $0.22 EPS.

A number of other analysts also recently weighed in on CELC. Weiss Ratings downgraded shares of Celcuity from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Wells Fargo & Company reduced their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research report on Wednesday. Craig Hallum dropped their price target on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Wolfe Research reiterated an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research note on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $152.09.

Celcuity Stock Down 2.7%

NASDAQ:CELC opened at $88.95 on Thursday. The firm’s 50-day moving average price is $122.64 and its 200-day moving average price is $111.55. The company has a market capitalization of $4.34 billion, a PE ratio of -22.81 and a beta of 0.10. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. Celcuity has a 1-year low of $11.27 and a 1-year high of $151.02.

Celcuity (NASDAQ:CELC) last released its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. lifted its stake in Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after acquiring an additional 86 shares during the period. Ogorek Anthony Joseph NY ADV lifted its stake in Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after acquiring an additional 109 shares during the period. US Bancorp DE lifted its stake in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the period. Intech Investment Management LLC lifted its stake in Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock valued at $1,295,000 after acquiring an additional 183 shares during the period. Finally, Aristides Capital LLC lifted its stake in Celcuity by 2.0% during the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock valued at $1,526,000 after acquiring an additional 303 shares during the period. Institutional investors own 63.33% of the company’s stock.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at $949,509.60. The trade was a 57.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is currently owned by company insiders.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Several analysts and commentary pieces said the selloff may be overdone, noting that gedatolisib still showed strong progression-free survival and response-rate benefits and could support blockbuster potential in a multi-billion-dollar breast cancer market. Celcuity: Selloff On Yesterday’s Data Unwarranted – Buy Rating Upheld
• Positive Sentiment: HC Wainwright lowered its price target to $145 from $185 but kept a buy rating, implying substantial upside from current levels. HC Wainwright rating update via Benzinga/The Fly
• Positive Sentiment: Management said FDA approval is expected by July 2026 for one breast-cancer subgroup, with an additional filing planned for the mutant cohort, keeping the regulatory catalyst in focus. Convertible notes offering announcement
• Neutral Sentiment: Celcuity announced a proposed $400 million offering of convertible senior notes due 2032, which strengthens financing capacity but also raises potential dilution and capital structure concerns. Celcuity convertible senior notes offering
• Negative Sentiment: Initial reaction to the Phase 3 readout was negative because investors judged the results against lofty expectations, with several reports saying the breast-cancer data “disappointed” despite remaining competitive. Reuters article on Celcuity plunge

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.